Back to MPT Database

ARV/Contraceptive Long-Acting MPT Injectable

Silica hydrogel-based long-acting injectable delivering an ARV and a contraceptive. Currently in preclinical development.

For more information, contact: Gustavo Doncel at doncelgf@odu.edu/conradinnovations@odu.edu

Development Stage:

Preclinical – Early (Pre1)

Hormonal/Non-Hormonal:

Hormonal

Delivery Route & Method:

Systemic - Injectable (Subcutaneous)

Mechanism of Action:

Integrase strand-transfer inhibitor

Developer:

  • CONRAD

Funding:

  • National Institutes of Health (NIH)

Funding Mechanism:

NIH R33 Horizon

Past Funding:

National Institutes of Health (NIH R-61)
Eastern Virginia Medical School (EVMS, now part of Virginia Health Sciences at Old Dominion University)
U.S Agency for International Development (USAID)
NIH Adolescent Medicines Trial Network for HIV Interventions (ATN)

Active Ingredient(s):

  • Antiretroviral (ARV)
  • Hormonal Contraceptive (unspecified)

Product Indication(s):

  • HIV
  • Unintended Pregnancy

Useful Links:

Back to MPT Database